# Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer

> **NCT07702305** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 15 (estimated)

## Conditions studied

- EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

## Interventions

- **DRUG:** Sacituzumab tirumotecan

## Key facts

- **NCT ID:** NCT07702305
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-23
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702305, "Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*